A further seventeen new comedications have been added to the interaction checker:
We have had a busy few months recently and a significant target has been achieved with the latest new drugs for the comedication list. These new additions take the number of drugs on the comedication list to over 1000! The new drugs and their classes are shown below:
After adding many new cancer therapies recently, we have returned to the list of requested drugs from the survey we had on the website last year and have added the following drugs.
These four new drugs were highly requested in the survey with each having more than 10 r...
We have completed our current planned expansion of the cancer therapies in the comedication list with seven new drugs being added:
The work on the cancer therapies during July and August takes the number of drugs in this c...
We have added the monoclonal antibody vilobelimab to the Covid-19 Host-directed Therapies class of primary drugs.
In April, the FDA granted an emergency use authorization for the use of vilobelimab (Gohibic®, InflaRx) for the treatment of COVID-19 in hospitalized adults when administered within 48 hours of mechanical ventilation or extracorporeal membrane oxygenation. Vilobelimab is a...
For the next month or so, we will be focussing on expanding the number of cancer therapies in the comedication list.
The first batch of cancer drugs have been added and include:
A new drug entry has been created for when nirmatrelvir/ritonavir is used off-label for longer than the licenced treatment duration of 5 days. An extended treatment duration of nirmatrelvir/ritonavir may be used in a clinical trial setting or in patients who may be at risk of viral rebound with the standard 5 day treatment (for example, people with underlying medical conditions).
Our work on the list of requested drugs from the survey we had on the website last year continues with the addition of the following drugs.
Nine new comedications have been added to the interaction checker - 3 immuno-suppressants and 6 cancer therapies.
The new immuno-suppressants are abatacept, certolizumab pegol and ixekizumab.
The new cancer therapies are bevacizumab, cabazitaxel, chlorambucil, dacarbazine
Eight new drugs to be added to the comedication list in the interaction checker. The new drugs can be found in the following classes:
Analgesics - Ketoprofen
Cancer therapies- Carboplatin, Docetaxel, Doxorubicin, Gemcitabine, Oxaliplatin
Four new comedications have been added to the gastro-intestinal class of comedications on the interaction checker:
Two new comedications have been added to the interaction checker:
Two immunosuppressants have been added to the interaction checker.
Filgotinib (Jyseleca®) is a JAK inhibitor indicated for the treatment of rheumatoid arthritis or ulcerative colitis.
Risankizumab (Skyrizi®) is indicated for the treatment of plaque psoriasis and psoriatic arthritis, with an addition indication for active Crohn’s disease in the ...
Our Prescribing Resource with advice for administering COVID therapies to patients who cannot swallow tablets or capsules has been updated with additional advice for molnupiravir.
The FDA Emergency Use Authorization for molnupiravir now states that the capsules can be opened an...
Two comedications for the treatment of hypertriglyceridaemia have been added to the website. Icosapent ethyl and omega-3 fatty acids can be found in the lipid lowering class.
We are continuing to work through the list of requested drugs from the survey we had on the website last year with 7 more comedications being added to the website:
Ensitrelvir (Xocova®) is now included in the list of COVID therapies. Ensitrelvir is an oral antiviral agent developed by Shionogi & Co which obtained emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan in November 2022. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease. It is administered on...
The names of some comedications in the interaction checker have been revised with additional spellings and/or names. The changes are shown below and we hope that this will make the search process easier.
Following the introduction of the “look for alternatives” feature on the interaction checker (click here for details), we have reviewed the “Other” drug class and moved several comedications into new or existing classes.
Five new classes have been created and various comedications have been moved into the ...
Following the introduction of the new comedication class “Benign Prostatic Hyperplasia Therapies”, two new comedications have been added to the class.
We have collated a further batch of responses to the survey we had on the website last year which allowed users to request comedications for inclusion on the website.
In this this batch of responses (from April to August 2022 inclusive), we had ~1600 requests for nearly 400 drugs. We have combined these requests with the remaining drugs from the first set of results and during this...
Our comedication list is frequently expanding and currently there are nearly 900 drugs available on the interaction checker. The latest additions to the list are shown below.
If you use our other websites you may be familiar with the "look for alternatives" feature and we are pleased to announce that this feature is now available on interactions checker on the COVID-19 website.
If your drug search returns an amber or red interaction, clicking the blue "look for alternatives" button will open a table displaying all the drugs in your comedication class, and the...
Last year we had a survey on the website which allowed users to request comedications for inclusion on the website. In the first three months of the survey we had over 1000 requests for over 300 drugs. During 2022 we added drugs representing 77% of all the requests with our focus being on the drugs with the most requests.
All drugs with 4 or more requests have been added and we are...
The COVID-19 website has been running for nearly three years and we have decided to introduce a newsletter to help you keep up-to-date with what we are doing. The newsletter will include details of new drugs and prescribing resources added to the website, as well as details of conferences and educational events the team are organising.
We anticipate sending these newsletters approx...